Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1297 to 1307 of 1307 entries
Sorted by: Best Match Show Resources per page
Cyclophane Molecules Exhibiting Thermally Activated Delayed Fluorescence: Linking Donor Units to Influence Molecular Conformation.

The Journal of organic chemistry

Hempe M, Harrison AK, Ward JS, Batsanov AS, Fox MA, Dias FB, Bryce MR.
PMID: 33251794
J Org Chem. 2021 Jan 01;86(1):429-445. doi: 10.1021/acs.joc.0c02174. Epub 2020 Nov 28.

The synthetic methodology to covalently link donors to form cyclophane-based thermally activated delayed fluorescence (TADF) molecules is presented. These are the first reported examples of TADF cyclophanes with "electronically innocent" bridges between the donor units. Using a phenothiazine-dibenzothiophene-

Cite
Hempe M, Harrison AK, Ward JS, et al. Cyclophane Molecules Exhibiting Thermally Activated Delayed Fluorescence: Linking Donor Units to Influence Molecular Conformation. J Org Chem. 2020;86(1):429-445doi: 10.1021/acs.joc.0c02174.
Hempe, M., Harrison, A. K., Ward, J. S., Batsanov, A. S., Fox, M. A., Dias, F. B., & Bryce, M. R. (2021). Cyclophane Molecules Exhibiting Thermally Activated Delayed Fluorescence: Linking Donor Units to Influence Molecular Conformation. The Journal of organic chemistry, 86(1), 429-445. https://doi.org/10.1021/acs.joc.0c02174
Hempe, Matthias, et al. "Cyclophane Molecules Exhibiting Thermally Activated Delayed Fluorescence: Linking Donor Units to Influence Molecular Conformation." The Journal of organic chemistry vol. 86,1 (2021): 429-445. doi: https://doi.org/10.1021/acs.joc.0c02174
Hempe M, Harrison AK, Ward JS, Batsanov AS, Fox MA, Dias FB, Bryce MR. Cyclophane Molecules Exhibiting Thermally Activated Delayed Fluorescence: Linking Donor Units to Influence Molecular Conformation. J Org Chem. 2021 Jan 01;86(1):429-445. doi: 10.1021/acs.joc.0c02174. Epub 2020 Nov 28. PMID: 33251794.
Copy Download .nbib Format: NLM
Loading acetoxymethyl ester fluorescent dyes into the cytoplasm of Arabidopsis and Commelina guard cells.

The New phytologist

Kuchitsu K, Ward JM, Allen GJ, Schelle I, Schroeder JI.
PMID: 33863225
New Phytol. 2002 Mar;153(3):527-533. doi: 10.1046/j.0028-646X.2001.00346.x. Epub 2002 Mar 05.

•  Cytosolic calcium and pH changes are integral components of guard cell signal transduction. Acetoxymethyl (AM) ester-linked Ca

Cite
Kuchitsu K, Ward JM, Allen GJ, et al. Loading acetoxymethyl ester fluorescent dyes into the cytoplasm of Arabidopsis and Commelina guard cells. New Phytol. 2002;153(3):527-533doi: 10.1046/j.0028-646X.2001.00346.x.
Kuchitsu, K., Ward, J. M., Allen, G. J., Schelle, I., & Schroeder, J. I. (2002). Loading acetoxymethyl ester fluorescent dyes into the cytoplasm of Arabidopsis and Commelina guard cells. The New phytologist, 153(3), 527-533. https://doi.org/10.1046/j.0028-646X.2001.00346.x
Kuchitsu, Kazuyuki, et al. "Loading acetoxymethyl ester fluorescent dyes into the cytoplasm of Arabidopsis and Commelina guard cells." The New phytologist vol. 153,3 (2002): 527-533. doi: https://doi.org/10.1046/j.0028-646X.2001.00346.x
Kuchitsu K, Ward JM, Allen GJ, Schelle I, Schroeder JI. Loading acetoxymethyl ester fluorescent dyes into the cytoplasm of Arabidopsis and Commelina guard cells. New Phytol. 2002 Mar;153(3):527-533. doi: 10.1046/j.0028-646X.2001.00346.x. Epub 2002 Mar 05. PMID: 33863225.
Copy Download .nbib Format: NLM
Histology Atlas of the Developing Mouse Placenta.

Toxicologic pathology

Elmore SA, Cochran RZ, Bolon B, Lubeck B, Mahler B, Sabio D, Ward JM.
PMID: 34872401
Toxicol Pathol. 2022 Jan;50(1):60-117. doi: 10.1177/01926233211042270. Epub 2021 Dec 06.

The use of the mouse as a model organism is common in translational research. This mouse-human similarity holds true for placental development as well. Proper formation of the placenta is vital for development and survival of the maturing embryo....

Cite
Elmore SA, Cochran RZ, Bolon B, et al. Histology Atlas of the Developing Mouse Placenta. Toxicol Pathol. 2021;50(1):60-117doi: 10.1177/01926233211042270.
Elmore, S. A., Cochran, R. Z., Bolon, B., Lubeck, B., Mahler, B., Sabio, D., & Ward, J. M. (2022). Histology Atlas of the Developing Mouse Placenta. Toxicologic pathology, 50(1), 60-117. https://doi.org/10.1177/01926233211042270
Elmore, Susan A, et al. "Histology Atlas of the Developing Mouse Placenta." Toxicologic pathology vol. 50,1 (2022): 60-117. doi: https://doi.org/10.1177/01926233211042270
Elmore SA, Cochran RZ, Bolon B, Lubeck B, Mahler B, Sabio D, Ward JM. Histology Atlas of the Developing Mouse Placenta. Toxicol Pathol. 2022 Jan;50(1):60-117. doi: 10.1177/01926233211042270. Epub 2021 Dec 06. PMID: 34872401; PMCID: PMC8678285.
Copy Download .nbib Format: NLM
Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South.

Social work in public health

Reif S, Rao D, Wilson E, Beckwith N, Frey S, Cooper H, Ward D, Belden M.
PMID: 34464238
Soc Work Public Health. 2022 Jan 02;37(1):1-13. doi: 10.1080/19371918.2021.1965937. Epub 2021 Aug 31.

HIV-related stigma has been implicated as a contributor to the disproportionate impact of HIV in the US Deep South. However, effective interventions aimed at reducing HIV-related stigma are limited in the region. This study adapted and piloted an HIV-related...

Cite
Reif S, Rao D, Wilson E, et al. Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Soc Work Public Health. 2021;37(1):1-13doi: 10.1080/19371918.2021.1965937.
Reif, S., Rao, D., Wilson, E., Beckwith, N., Frey, S., Cooper, H., Ward, D., & Belden, M. (2022). Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Social work in public health, 37(1), 1-13. https://doi.org/10.1080/19371918.2021.1965937
Reif, Susan, et al. "Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South." Social work in public health vol. 37,1 (2022): 1-13. doi: https://doi.org/10.1080/19371918.2021.1965937
Reif S, Rao D, Wilson E, Beckwith N, Frey S, Cooper H, Ward D, Belden M. Adaptation and Preliminary Testing of an Intervention to Reduce Stigma among Individuals Living with HIV in the Deep South. Soc Work Public Health. 2022 Jan 02;37(1):1-13. doi: 10.1080/19371918.2021.1965937. Epub 2021 Aug 31. PMID: 34464238.
Copy Download .nbib Format: NLM
What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.

Gynecologic oncology

Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA.
PMID: 33972087
Gynecol Oncol. 2021 Jul;162(1):88-96. doi: 10.1016/j.ygyno.2021.04.038. Epub 2021 May 07.

OBJECTIVE: To prospectively measure cardiometabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared to a similar age comparison group, and the effects of Hormone Therapy (HT) on cardiometabolic risk.METHODS: Prospective observational study of 95 premenopausal women planning...

Cite
Hickey M, Moss KM, Mishra GD, et al. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol. 2021;162(1):88-96doi: 10.1016/j.ygyno.2021.04.038.
Hickey, M., Moss, K. M., Mishra, G. D., Krejany, E. O., Domchek, S. M., Wark, J. D., Trainer, A., & Wild, R. A. (2021). What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecologic oncology, 162(1), 88-96. https://doi.org/10.1016/j.ygyno.2021.04.038
Hickey, Martha, et al. "What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy." Gynecologic oncology vol. 162,1 (2021): 88-96. doi: https://doi.org/10.1016/j.ygyno.2021.04.038
Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA. What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. Gynecol Oncol. 2021 Jul;162(1):88-96. doi: 10.1016/j.ygyno.2021.04.038. Epub 2021 May 07. PMID: 33972087.
Copy Download .nbib Format: NLM
[No title available]

Journal of immunology (Baltimore, Md. : 1950)

Bagadia P, O'Connor KW, Wu R, Ferris ST, Ward JP, Schreiber RD, Murphy TL, Murphy KM.
PMID: 34135058
J Immunol. 2021 Jul 01;207(1):125-132. doi: 10.4049/jimmunol.1901010. Epub 2021 Jun 16.

The transcriptional repressor

Cite
Bagadia P, O'Connor KW, Wu R, et al. . J Immunol. 2021;207(1):125-132doi: 10.4049/jimmunol.1901010.
Bagadia, P., O'Connor, K. W., Wu, R., Ferris, S. T., Ward, J. P., Schreiber, R. D., Murphy, T. L., & Murphy, K. M. (2021). . Journal of immunology (Baltimore, Md. : 1950), 207(1), 125-132. https://doi.org/10.4049/jimmunol.1901010
Bagadia, Prachi, et al. "." Journal of immunology (Baltimore, Md. : 1950) vol. 207,1 (2021): 125-132. doi: https://doi.org/10.4049/jimmunol.1901010
Bagadia P, O'Connor KW, Wu R, Ferris ST, Ward JP, Schreiber RD, Murphy TL, Murphy KM. . J Immunol. 2021 Jul 01;207(1):125-132. doi: 10.4049/jimmunol.1901010. Epub 2021 Jun 16. PMID: 34135058.
Copy Download .nbib Format: NLM
Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer.

Cell death discovery

Falcicchio M, Ward JA, Macip S, Doveston RG.
PMID: 33298896
Cell Death Discov. 2020 Nov 16;6(1):126. doi: 10.1038/s41420-020-00362-3.

Most cancers evolve to disable the p53 pathway, a key tumour suppressor mechanism that prevents transformation and malignant cell growth. However, only ~50% exhibit inactivating mutations of p53, while in the rest its activity is suppressed by changes in...

Cite
Falcicchio M, Ward JA, Macip S, et al. Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer. Cell Death Discov. 2020;6(1):126doi: 10.1038/s41420-020-00362-3.
Falcicchio, M., Ward, J. A., Macip, S., & Doveston, R. G. (2020). Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer. Cell death discovery, 6(1), 126. https://doi.org/10.1038/s41420-020-00362-3
Falcicchio, Marta, et al. "Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer." Cell death discovery vol. 6,1 (2020): 126. doi: https://doi.org/10.1038/s41420-020-00362-3
Falcicchio M, Ward JA, Macip S, Doveston RG. Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer. Cell Death Discov. 2020 Nov 16;6(1):126. doi: 10.1038/s41420-020-00362-3. PMID: 33298896; PMCID: PMC7669891.
Copy Download .nbib Format: NLM
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.

Cancers

Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM.
PMID: 33327406
Cancers (Basel). 2020 Dec 14;12(12). doi: 10.3390/cancers12123755.

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This is particularly relevant in a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns tumor heterogeneity and cancer dormancy...

Cite
Umbreit EC, Siddiqui BA, Hwang MJ, et al. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020;12(12)doi: 10.3390/cancers12123755.
Umbreit, E. C., Siddiqui, B. A., Hwang, M. J., Joon, A. Y., Maity, T., Westerman, M. E., Merriman, K. W., Alhasson, H., Uthup, J., Guo, T., Moore, J. A., Ward, J. F., Karam, J. A., Wood, C. G., Pisters, L. L., Zhang, M., & Tu, S. M. (2020). Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers, 12(12), . https://doi.org/10.3390/cancers12123755
Umbreit, Eric C, et al. "Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor." Cancers vol. 12,12 (2020). doi: https://doi.org/10.3390/cancers12123755
Umbreit EC, Siddiqui BA, Hwang MJ, Joon AY, Maity T, Westerman ME, Merriman KW, Alhasson H, Uthup J, Guo T, Moore JA, Ward JF, Karam JA, Wood CG, Pisters LL, Zhang M, Tu SM. Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers (Basel). 2020 Dec 14;12(12). doi: 10.3390/cancers12123755. PMID: 33327406; PMCID: PMC7764868.
Copy Download .nbib Format: NLM
OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data.

Radiology. Artificial intelligence

Halling-Brown MD, Warren LM, Ward D, Lewis E, Mackenzie A, Wallis MG, Wilkinson LS, Given-Wilson RM, McAvinchey R, Young KC.
PMID: 33937853
Radiol Artif Intell. 2020 Nov 25;3(1):e200103. doi: 10.1148/ryai.2020200103. eCollection 2021 Jan.

Cite
Halling-Brown MD, Warren LM, Ward D, et al. OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data. Radiol Artif Intell. 2020;3(1):e200103doi: 10.1148/ryai.2020200103.
Halling-Brown, M. D., Warren, L. M., Ward, D., Lewis, E., Mackenzie, A., Wallis, M. G., Wilkinson, L. S., Given-Wilson, R. M., McAvinchey, R., & Young, K. C. (2021). OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data. Radiology. Artificial intelligence, 3(1), e200103. https://doi.org/10.1148/ryai.2020200103
Halling-Brown, Mark D, et al. "OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data." Radiology. Artificial intelligence vol. 3,1 (2021): e200103. doi: https://doi.org/10.1148/ryai.2020200103
Halling-Brown MD, Warren LM, Ward D, Lewis E, Mackenzie A, Wallis MG, Wilkinson LS, Given-Wilson RM, McAvinchey R, Young KC. OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data. Radiol Artif Intell. 2020 Nov 25;3(1):e200103. doi: 10.1148/ryai.2020200103. eCollection 2021 Jan. PMID: 33937853; PMCID: PMC8082293.
Copy Download .nbib Format: NLM
Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies.

European journal of cancer (Oxford, England : 1990)

Chambers BS, Ward D, Webster R, Tunnard V, Hill QA.
PMID: 34998047
Eur J Cancer. 2022 Jan 05;162:158-160. doi: 10.1016/j.ejca.2021.11.031. Epub 2022 Jan 05.

No abstract available.

Cite
Chambers BS, Ward D, Webster R, et al. Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. Eur J Cancer. 2022;162:158-160doi: 10.1016/j.ejca.2021.11.031.
Chambers, B. S., Ward, D., Webster, R., Tunnard, V., & Hill, Q. A. (2022). Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. European journal of cancer (Oxford, England : 1990), 162158-160. https://doi.org/10.1016/j.ejca.2021.11.031
Chambers, Bradley S, et al. "Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies." European journal of cancer (Oxford, England : 1990) vol. 162 (2022): 158-160. doi: https://doi.org/10.1016/j.ejca.2021.11.031
Chambers BS, Ward D, Webster R, Tunnard V, Hill QA. Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. Eur J Cancer. 2022 Jan 05;162:158-160. doi: 10.1016/j.ejca.2021.11.031. Epub 2022 Jan 05. PMID: 34998047.
Copy Download .nbib Format: NLM
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.

Circulation

Felker GM, Butler J, Ibrahim NE, Piña IL, Maisel A, Bapat D, Camacho A, Ward JH, Williamson KM, Solomon SD, Januzzi JL.
PMID: 34251893
Circulation. 2021 Jul 13;144(2):180-182. doi: 10.1161/CIRCULATIONAHA.121.054034. Epub 2021 Jul 12.

No abstract available.

Cite
Felker GM, Butler J, Ibrahim NE, et al. Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation. 2021;144(2):180-182doi: 10.1161/CIRCULATIONAHA.121.054034.
Felker, G. M., Butler, J., Ibrahim, N. E., Piña, I. L., Maisel, A., Bapat, D., Camacho, A., Ward, J. H., Williamson, K. M., Solomon, S. D., Januzzi, J. L. (2021). Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 144(2), 180-182. https://doi.org/10.1161/CIRCULATIONAHA.121.054034
Felker, G Michael, et al. "Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF." Circulation vol. 144,2 (2021): 180-182. doi: https://doi.org/10.1161/CIRCULATIONAHA.121.054034
Felker GM, Butler J, Ibrahim NE, Piña IL, Maisel A, Bapat D, Camacho A, Ward JH, Williamson KM, Solomon SD, Januzzi JL. Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation. 2021 Jul 13;144(2):180-182. doi: 10.1161/CIRCULATIONAHA.121.054034. Epub 2021 Jul 12. PMID: 34251893; PMCID: PMC8270225.
Copy Download .nbib Format: NLM
Showing 1297 to 1307 of 1307 entries